sorry about the camera man he has parkinsons disease…

"It was so frustrating, like a mystery I couldn’t solve.” Cue: extreme close-up of an average-looking American soccer-mom type. Cut to: bedroom scene with the same woman thrashing around her bed, trying to get comfortable. "Night after night, strange sensations in my legs. I had to get up and move when all I wanted to do was rest.” If you’ve watched television within the last year, you’ve ...

XenoPort Inc., which missed out on an anticipated $23 million milestone payment this quarter after partner GlaxoSmithKline plc yanked the new drug application for Solzira in restless legs syndrome (RLS) due to a filing glitch, beefed up its balance sheet with a $40 million registered direct offering.

Ahead of Solzira Resubmission, XenoPort Adds $40M in Offering TMCnet - Dec 30, 2008 Existing drugs Requip (ropinirole, GSK) and Mirapex (pramiprexole, Boehringer Ingelheim GmbH) both target the dopamine receptor. ...

Discover Magazine

Stakeholder Opinions - Restless Legs Syndrome - Novel drugs to ... Live-PR.com (Pressemitteilung), Austria - Dec 18, 2008 Through Requip (ropinirole) and Mirapex´s (pramipexole) regulatory approvals in 200506, GlaxoSmithKline and Boehringer Ingelheim pioneered the on-label RLS ... What’s in a Name? Real Diseases Suffer from Silly Name Syndrome Discover Magazine all 2 news articles